Plain-English translation of NCT06618872 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a newer brain imaging scan called [18F]RO948 tau-PET can help doctors diagnose Alzheimer's disease better than the standard scan currently used (amyloid-PET). You would receive both types of scans so researchers can compare how helpful each one is at detecting the disease early, when treatment might be most effective.
While doctors know that both types of brain scans can show signs of Alzheimer's disease, the newer scan has never been formally tested to see if it actually helps doctors make better or faster diagnoses in real-world practice. This study will answer that important question.
You likely qualify if…
You likely don't qualify if…
You would receive two brain imaging scans—one amyloid-PET scan (standard care) and one tau-PET scan (the newer experimental scan). The study will randomly decide which scan you receive first. Both scans involve lying still in a machine while it takes detailed pictures of your brain; each scan takes about an hour. You would also complete some memory and thinking tests, and the study team would review your MRI from the past 6 months.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Switzerland
Sponsor
University Hospital, Geneva
Collaborators
Centre Hospitalier Universitaire Vaudois
Enrollment target
~120 participants
Started
December 2024
Primary completion
August 2027
Age range
50 Years – 85 Years
Last updated on clinicaltrials.gov in December 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Valentina Garibotto, MD
University Hospital, Geneva
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.